ReviewDiseases (Basel, Switzerland)2017
Targeting Metabolic Modulation and Mitochondrial Dysfunction in the Treatment of Heart Failure.
Review in Diseases (Basel, Switzerland), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Association between intake of red and processed meat and the risk of heart failure: a meta-analysis.BMC public health · 2019Pooled it
- Mitochondrial Dysfunction in Cardiac Disease: The Fort Fell.Biomolecules · 2024Review
- Tumor necrosis factor induces pathogenic mitochondrial ROS in tuberculosis through reverse electron transport.Science (New York, N.Y.) · 2022Article
- Animal Models of Dysregulated Cardiac Metabolism.Circulation research · 2022Review
- Long-term treatment with Elamipretide enhances healthy aging phenotypes in mice.Aging pathobiology and therapeutics · 2022Article
- Protective Effect of Trimetazidine on Potassium Ion Homeostasis in Myocardial Tissue in Mice with Heart Failure.BioMed research international · 2022Article
- Selenoprotein DIO2 Is a Regulator of Mitochondrial Function, Morphology and UPRmt in Human Cardiomyocytes.International journal of molecular sciences · 2021Article
- Pathophysiology and Treatment of Hypertrophic Cardiomyopathy: New Perspectives.Current heart failure reports · 2021Review
- Heart Metabolism in Sepsis-Induced Cardiomyopathy-Unusual Metabolic Dysfunction of the Heart.International journal of environmental research and public health · 2021Review
- Preventative therapeutic approaches for hypertrophic cardiomyopathy.The Journal of physiology · 2021Review
- Neuroprotective Effects of a Small Mitochondrially-Targeted Tetrapeptide Elamipretide in Neurodegeneration.Frontiers in integrative neuroscience · 2021Review
- Review
- Use of a Systematic Pharmacological Methodology to Explore the Mechanism of Shengmai Powder in Treating Diabetic Cardiomyopathy.Medical science monitor : international medical journal of experimental and clinical research · 2020Article
- Mitochondrial Dynamics in Adult Cardiomyocytes and Heart Diseases.Frontiers in cell and developmental biology · 2020Review
- Mechanisms of Anthracycline-Induced Cardiotoxicity: Is Mitochondrial Dysfunction the Answer?Frontiers in cardiovascular medicine · 2020Review
- Protective effects of trimetazidine and coenzyme Q10 on cisplatin-induced cardiotoxicity by alleviating oxidative stress and mitochondrial dysfunction.Anatolian journal of cardiology · 2019Article
- Cardiac Insulin Resistance in Heart Failure: The Role of Mitochondrial Dynamics.International journal of molecular sciences · 2019Review
- Elamipretide Improves Mitochondrial Function in the Failing Human Heart.JACC. Basic to translational science · 2019Article
- Targeting Mitochondrial Function in Heart Failure: Makes Sense But Will it Work?JACC. Basic to translational science · 2019Article
- Novel Insights and Treatment Strategies for Right Heart Failure.Current heart failure reports · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Despite significant improvements in morbidity and mortality with current evidence-based pharmaceutical-based treatment of heart failure (HF) over the previous decades, the burden of HF remains high. An alternative approach is currently being developed, which targets myocardial energy efficiency and the dysfunction of the cardiac mitochondria. Emerging evidence suggests that the insufficient availability of ATP to the failing myocardium can be attributed to abnormalities in the myocardial utilisation of its substrates rather than an overall lack of substrate availability. Therefore, the development of potential metabolic therapeutics has commenced including trimetazidine, ranolazine and perhexiline, as well as specific mitochondrial-targeting pharmaceuticals, such as elamipretide. Large randomised controlled trials are required to confirm the role of metabolic-modulating drugs in the treatment of heart failure, but early studies have been promising in their possible efficacy for the management of heart failure in the future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.